EDIT vs MMC · rev $32.3M vs P/E 22, rev $24.46B
Editas Medicine Inc (EDIT) versus Marsh & McLennan Companies Inc (MMC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
EDIT currently screens at market cap $375.2M. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Not investment advice. Open the EDIT and MMC stock pages for the full models.
Not investment advice.